293 related articles for article (PubMed ID: 19341184)
1. Biological therapy of inflammatory bowel disease.
Owczarek D; Cibor D; Szczepanek M; Mach T
Pol Arch Med Wewn; 2009; 119(1-2):84-8. PubMed ID: 19341184
[TBL] [Abstract][Full Text] [Related]
2. Crohn's targeted therapy: myth or real goal?
Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
[TBL] [Abstract][Full Text] [Related]
3. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
4. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
5. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
10. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
Tursi A
Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576
[TBL] [Abstract][Full Text] [Related]
11. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
13. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
14. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
Barrie A; Regueiro M
Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
[TBL] [Abstract][Full Text] [Related]
19. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
20. Novel biologics in inflammatory bowel disease.
Papachristou GI; Plevy S
Gastroenterol Clin North Am; 2004 Jun; 33(2):251-69, ix. PubMed ID: 15177537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
